Top Markets
Coin of the day
Novacyt S.A. Novacyt S.A.

Novacyt S.A.

ALNOV
株式のランク #26248
Founded in 2006 and headquartered in Vélizy-Villacoublay, France, Novacyt S.A.... Founded in 2006 and headquartered in Vélizy-Villacoublay, France, Novacyt S.A. and its subsidiaries are actively involved in the full lifecycle of diagnostic products, encompassing development, manufacturing, custom design, and global commercialization. These vital diagnostic tools are employed in the detection of both cancer and a variety of infectious diseases. The company boasts an extensive international reach, serving markets throughout the United Kingdom, wider Europe, the United States, the Asia Pacific region, the Middle East, and Africa. Novacyt's operations are structured around three core segments. Primer Design specializes in the creation, production, and sale of molecular real-time qPCR testing devices and reagents, primarily for infectious disease diagnostics. Lab21 Products focuses on developing, manufacturing, and distributing a diverse portfolio of protein-based in-vitro diagnostic (IVD) products, also targeting infectious diseases. The IT-IS International segment is dedicated to engineering and fabricating PCR instruments used in the life sciences and food testing industries. The company's clientele principally includes hospitals and various corporate organizations.
株価
$0.58121603
時価総額
$42.14M
変化(1日)
-4.48%
変化(1年)
6.58%
FR
取引 Novacyt S.A. (ALNOV)

カテゴリー

Novacyt S.A.(ALNOV)の収益
Aug 2026 時点の収益 TTM: 0
Novacyt S.A. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Novacyt S.A. の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差
$46.59B -
US
$25.84B -
US
$35.48B -
IE
$21.00B -
US
- -
DE